PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Puberty, Precocious”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 973 records · Page 54Linked to original sources
PubMedDate not supplied

[Short-term comparison of the treatment of precocious puberty with 2 different LHRH antagonists (buserelin and long-acting triptorelin). An endocrinologic and echographic study].

To compare the short term effects of a short (Buserelin, 1800 micrograms/day as nasal spray) and a long acting (Triptorelin Depot, 3.75 mg/every 4 weeks i.m.) LHRH agonist, LH and FSH (LHRH test and 2 hours spontaneous rhythm during the morning and during the evening), estradiol and pelvic ultrasonography were evaluated in 12 children (1 boy, mean age 8.24 +/- 1.39 years, mean bone age 9.39 +/- 1.76 years) with early puberty before and after 1 and 2 months of treatment. Informed consent was obtained in all the cases. 6 patients started with Buserelin and 6 with Triptorelin. The therapeutic regimen was crossed over after 2 months of treatment and 2 more months of treatment withdrawal. The results indicate that while in both groups FSH values decreased significantly already from the last month of treatment, patients treated with Triptorelin showed a later LH decrease (significant only after 2 months of treatment). A decrease of pelvic structures volume was however evident only in patients treated with Triptorelin. After 2 months of treatment estradiol levels lowered (but not significantly) in both group. In conclusion despite a later LH decrement, patients treated with the long acting analogue showed however a more evident reduction of pelvic organs volume.

Buserelin↗
PubMed1994

[Complete isosexual precocious puberty (true, LHRH-dependent)-- personal experience].

The authors examined a group of 10 girls with true sexual precocity. The age of the patients was within the range of 11 months and seven and a half years. Height acceleration was on average almost one year, skeletal age acceleration was on average almost one and a half years; when BA was evaluated according to tables of visualization methods of the Motol Clinic and the TW2 and C method, a marked acceleration of BA was observed in the RUS method. To differentiate incomplete puberty-thelarche-in all girls the stimulation test, using Relefact LHRH (Hoechst), was performed, the diagnosis of true puberty was suggested by LH serum levels elevated above 12 IU/l. In incomplete puberty only FSH was elevated. In all patients oestrogenization of the vaginal epithelium, breast development (M2-3) and pubic hair was present, in three patients menarche. For treatment Decapeptyl-Depot (Ferring) was administered, the longest period of treatment was eight months. Therefore the change of HA and BA was not evaluated, but even during this brief period of treatment regression of pubertal sex signs occurred.

Child↗